Vitrectomized vs non-vitrectomized eyes in DEX implant treatment for DMO-Is there any difference? the VITDEX study.

ABSTRACT:

Objective

We aimed to compare visual and anatomical outcome in vitrectomized and non-vitrectomized eyes treated with dexamethasone (DEX) implant due to diabetic macular oedema (DMO).

Design

Multicenter, retrospective, interventional study.

Participants

236 eyes from 234 patients with DMO with or without previous vitrectomy performed with follow-up of 12 months.

Methods

Records were reviewed for cases of DMO treated with DEX implant in vitrectomized and not vitrectomized eyes. Best corrected visual acuity (BCVA), central subfoveal thickness (CST), and intraocular pressure (IOP) were recorded at baseline and 12 months after treatment with DEX implants. Correlations between vitreous status and visual and anatomical outcome, as well as safety profile were analysed.

SUBMITTER: Iglicki M 

PROVIDER: S-EPMC9873723 | biostudies-literature | 2023 Feb

REPOSITORIES: biostudies-literature